VCA Antech, Inc. Reports Fourth Quarter 2008 Results and Provides Financial Guidance for 2009

VCA Antech, Inc. (NASDAQ: WOOF), a leading animal healthcare company in the United States, today reported financial results for the quarter ended December 31, 2008, as follows: revenue increased 6.7% to a fourth quarter record of $303.2 million; gross profit increased 6.6% to $73.9 million; operating income increased 6.5% to $50.9 million; net income increased 4.3% to $25.7 million; and diluted earnings per share increased 3.4% to $0.30. Each fourth quarter of 2008 and 2007 included a benefit of $3.3 million and $3.5 million, respectively related to a decline in our estimated workers' compensation liability for previous years' policy periods. The benefit totaled $2.0 million and $2.2 million on an after-tax basis or $0.02 and $0.03 per diluted common share in 2008 and 2007, respectively.

We also reported our financial results for the year ended December 31, 2008, as follows: revenue increased 10.5% to a twelve-month record of $1.28 billion; gross profit increased 6.6% to $342.6 million; operating income increased 7.9% to $251.7 million; net income increased 9.9% to $133.0 million; and diluted earnings per share increased 9.9% to $1.55. The years ended December 31, 2008 and 2007 each included a benefit of $3.3 million and $3.5 million, respectively, or $0.02 per diluted share on an after-tax basis related to a decline in our estimated workers' compensation liability, as mentioned previously.

Bob Antin, Chairman and CEO, stated, “Although the challenging economic environment has impacted our ability to maintain historical organic growth rates, we have extended our long record of revenue and earnings growth. We remain focused on our clients and their pets, and we are proud of the professionals and staff in our hospitals who continue to have the trust of the pet owning community.

“Animal hospital revenue in the fourth quarter increased 9.4% to $229.0 million driven by acquisitions. Our consolidated animal hospital gross margin increased to 17.5% compared to 16.0% and the operating margin increased to 15.2% compared to 13.3% primarily due to the implementation of cost controls and synergies achieved from the larger revenue base. Although our same-store revenue remained essentially flat during the quarter, our same-store gross profit margin increased to 18.3% compared to 16.2%.

“We continue to focus on our hospital acquisition program. During the fourth quarter we acquired eight animal hospitals with over $31.7 million of annualized revenue, bringing the twelve-month total to $118.0 million.

“Laboratory revenue in the fourth quarter increased 1.0% to $69.3 million driven by acquisitions as internal revenue remained essentially flat. Laboratory margins in the fourth quarter continued to be impacted by the aforementioned economic environment. Our laboratory gross profit margin declined to 42.3% from 45.9% for the quarter ended December 31, 2008 and 2007, respectively, and our laboratory operating margin declined to 34.3% from 38.9% for the quarter ended December 31, 2008 and 2007, respectively.”

2009 Financial Guidance

Our financial guidance for 2009 is as follows:

  • Revenue from $1.36 billion to $1.39 billion;
  • Net income from $135.2 million to $141.1 million; and
  • Diluted earnings per common share from $1.56 to $1.63.

Conference Call

We will discuss our company's fourth quarter and annual 2008 financial results during a conference call today, February 19, 2009, at 4:30 p.m. Eastern Time. You can access a live broadcast of the call by visiting our website at http://investor.vcaantech.com. You can also access the call via telephone by dialing 800-259-2693. Interested parties should call at least ten minutes prior to the start of the call to register.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our financial guidance for fiscal year 2009. Actual results may and likely will differ materially from the guidance provided in this release. Among the important factors that could cause actual results to differ are: a material adverse change in our financial condition or operations; the impact of adverse trends in the general economy on the rate of our laboratory internal revenue growth and animal hospital same-store revenue growth; the level of direct costs and our ability to maintain revenue and expenses at a level necessary to maintain expected operating margins; the level of selling, general and administrative costs; the effects of our recent acquisitions and our ability to effectively manage our growth and achieve operating synergies; a decline in demand for some of our products and services; any disruption in our information technology systems or transportation networks; the effects of competition; any impairment in the carrying value of our goodwill and other intangible assets; changes in prevailing interest rates; our ability to service our debt; and general economic conditions. These and other risk factors are discussed in our Report on Form 10-K for the year ended December 31, 2007, and our Report on Form 10-Q for the quarter ended September 30, 2008, and the reader is directed to these statements for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements.

We own, operate and manage the largest networks of freestanding veterinary hospitals and veterinary-exclusive clinical laboratories in the country, and we supply diagnostic imaging equipment to the veterinary industry.

 
VCA Antech, Inc.
Consolidated Income Statements
(Unaudited)
(In thousands, except per share amounts)
 
    Three Months Ended   Year Ended
    December 31,   December 31,
    2008   2007   2008   2007
Revenue:                
Animal hospital   $ 229,043     $ 209,298     $ 959,395     $ 844,344  
Laboratory     69,318       68,622       304,952       295,695  
Medical technology     12,944       13,925       51,177       46,823  
Intercompany     (8,136 )     (7,687 )     (38,054 )     (30,717 )
      303,169       284,158       1,277,470       1,156,145  
                 
Direct costs     229,297       214,837       934,833       834,724  
                 
Gross profit:                
Animal hospital     40,142       33,588       184,185       163,053  
Laboratory     29,294       31,466       142,783       143,072  
Medical technology     4,571       4,522       18,028       15,879  
Intercompany     (135 )     (255 )     (2,359 )     (583 )
      73,872       69,321       342,637       321,421  
                 
Selling, general and administrative expense:                
Animal hospital     5,327       5,270       22,142       21,562  
Laboratory     5,502       4,776       20,816       19,648  
Medical technology     2,835       3,139       12,337       11,528  
Corporate     9,073       7,881       35,432       34,139  
      22,737       21,066       90,727       86,877  
                 
Write-down and loss on sale of assets     201       448       234       1,323  
                 
Operating income     50,934       47,807       251,676       233,221  
                 
Interest expense, net     7,190       8,129       28,559       29,503  
Other (income) expense     (73 )     89       (97 )     315  
Minority interest     886       694       4,011       3,755  

Income before provision for income taxes

    42,931       38,895       219,203       199,648  
Provision for income taxes     17,240       14,272       86,219       78,636  
Net income   $ 25,691     $ 24,623     $ 132,984     $ 121,012  
                 
Diluted earnings per share   $ 0.30     $ 0.29     $ 1.55     $ 1.41  

Shares used for computing diluted earnings per share

    85,227       86,080       85,700       85,716  

 

 
VCA Antech, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands)
 
  December 31,
  2008   2007
Assets      
       
Current assets:      
Cash and cash equivalents $ 88,959     $ 110,866  
Trade accounts receivable, net   43,453       42,650  
Inventory   26,631       25,517  
Prepaid expenses and other   18,800       15,307  
Deferred income taxes   15,938       14,402  
Prepaid income taxes   5,287       8,160  
Total current assets   199,068       216,902  
Property and equipment, net   263,443       214,020  
Other assets:      
Goodwill   922,057       821,967  
Other intangible assets, net   35,645       22,373  
Deferred financing costs, net   1,067       1,537  
Other   27,758       9,912  
Total assets $ 1,449,038     $ 1,286,711  
       
Liabilities and Stockholders' Equity      
       
Current liabilities:      
Current portion of long-term obligations $ 7,771     $ 7,886  
Accounts payable   26,087       28,092  
Accrued payroll and related liabilities   42,840       38,341  
Other accrued liabilities   46,424       42,074  
Total current liabilities   123,122       116,393  
Long-term obligations, less current portion   544,860       552,294  
Deferred income taxes   47,331       28,197  
Other liabilities   9,890       11,236  
Minority interest   12,846       10,207  
Stockholders' equity:      
Common stock   85       84  
Additional paid-in capital   308,674       296,037  
Retained earnings   408,582       275,598  
Accumulated other comprehensive loss   (6,352 )     (3,335 )
Total stockholders' equity   710,989       568,384  
Total liabilities and stockholders' equity $ 1,449,038     $ 1,286,711  

 

 
VCA Antech, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
 
    Year Ended
    December 31,
    2008   2007
Cash flows from operating activities:        
Net income   $ 132,984     $ 121,012  

Adjustments to reconcile net income to net cash provided by operating activities:

       
Depreciation and amortization     31,911       27,049  
Amortization of debt costs     470       368  
Provision for uncollectible accounts     5,187       5,053  
Write-down and loss on sale of assets     234       1,323  
Share-based compensation     7,176       4,584  
Minority interest in income of subsidiaries     4,011       3,755  
Distributions to minority interest partners     (3,987 )     (3,388 )
Deferred income taxes     20,425       10,940  
Excess tax benefit from exercise of stock options     (1,769 )     (7,866 )
Other     101       (113 )
Changes in operating assets and liabilities:        
Accounts receivable     (5,674 )     (2,687 )
Inventory, prepaid expenses and other assets     (6,981 )     (4,712 )
Accounts payable and other accrued liabilities     (2,515 )     7  
Accrued payroll and related liabilities     4,863       1,154  
Prepaid income taxes     6,885       13,897  

Net cash provided by operating activities

    193,321       170,376  
Cash flows from investing activities:        
Business acquisitions, net of cash acquired     (126,702 )     (215,523 )
Real estate acquired in connection with business acquisitions     (17,593 )     (7,962 )
Property and equipment additions     (55,045 )     (48,714 )
Proceeds from sale of assets     1,775       1,674  
Other     (15,146 )     (780 )
Net cash used in investing activities     (212,711 )     (271,305 )
Cash flows from financing activities:        
Repayment of long-term obligations     (7,790 )     (8,238 )
Proceeds from the issuance of long-term obligations     -       160,000  
Borrowings on revolving credit facility     35,000       -  
Repayment on revolving credit facility     (35,000 )     -  
Payment of financing costs     -       (926 )
Proceeds from issuance of common stock under stock option plans     3,606       7,989  
Excess tax benefit from exercise of stock options     1,769       7,866  
Net cash (used in) provided by financing activities     (2,415 )     166,691  
Effect of currency exchange rate changes on cash and cash equivalents     (102 )     -  
(Decrease) increase in cash and cash equivalents     (21,907 )     65,762  
Cash and cash equivalents at beginning of period     110,866       45,104  
Cash and cash equivalents at end of period   $ 88,959     $ 110,866  

 

 
VCA Antech, Inc.
Supplemental Operating Data
(In thousands, except per share amounts)
 
Table #1

 

 

 

 

 

Impact of workers' compensation adjustment on diluted earnings per share:

 

Three Months Ended
December 31,

 

Year Ended
December 31,

 

  2008   2007   2008   2007

Workers' compensation adjustment, net of tax

  $ 2,005     $ 2,167     $ 2,005     $ 2,167  

Shares used for computing diluted earnings per share

    85,227       86,080       85,700       85,716  

Impact of workers' compensation adjustment on diluted earnings per share (1)

  $ 0.02     $ 0.03     $ 0.02     $ 0.02  
                 

(1) The impact of the workers' compensation adjustment may not calculate exactly due to rounding.

                 
Table #2  

 

 

 

         
Workers' compensation adjustment  

Three Months Ended
December 31,

 

Year Ended
December 31,

    2008   2007   2008   2007
Included in direct costs:                
Animal Hospital   $ 2,457     $ 2,655     $ 2,457     $ 2,655  
Laboratory     456       493       456       493  
Medical Technology     30       62       30       62  
      2,943       3,210       2,943       3,210  

Included in selling, general and administrative expense:

               
Animal Hospital     109       121       109       121  
Laboratory     97       104       97       104  
Medical Technology     27       -       27       -  
Corporate     106       113       106       113  
      339       338       339       338  
Total workers' compensation adjustment     3,282       3,548       3,282       3,548  
Tax benefit     (1,277 )     (1,381 )     (1,277 )     (1,381 )

Workers' compensation adjustment, net of tax

    2,005       2,167       2,005       2,167  

 

 
VCA Antech, Inc.
Supplemental Operating Data - Continued
(In thousands)
 

Table #3

 

Selected consolidated balance sheet data

  December 31,

 

  2008   2007
         
Debt:        
Revolving credit facility   $ -     $ -  
Senior term notes     522,282       527,675  
Other debt and capital leases     30,349       32,505  
Total debt   $ 552,631     $ 560,180  
 

Table #4

 

Selected expense data

  Three Months Ended   Year Ended

 

  December 31,   December 31,

 

  2008   2007   2008   2007
                 
Rent expense   $ 11,090     $ 9,755     $ 42,709     $ 36,864  
                 

Depreciation and amortization included in direct costs:

               
Animal hospital   $ 5,517     $ 4,825     $ 21,464     $ 17,353  
Laboratory     1,936       1,713       7,269       6,356  
Medical technology     103       304       1,032       1,201  
Intercompany     (177 )     (105 )     (591 )     (386 )
      7,379       6,737       29,174       24,524  

Depreciation and amortization included in selling, general and administrative expense

    770       548       2,737       2,525  
Total depreciation and amortization   $ 8,149     $ 7,285     $ 31,911     $ 27,049  
                 

Share-based compensation included in direct costs:

               
Laboratory   $ 147     $ 159     $ 758     $ 661  
                 

Share-based compensation included in selling, general and administrative expense:

               
Animal hospital     341       297       1,568       1,193  
Laboratory     290       179       1,097       731  
Medical technology     67       30       208       111  
Corporate     1,022       490       3,545       1,888  
      1,720       996       6,418       3,923  
Total share-based compensation   $ 1,867     $ 1,155     $ 7,176     $ 4,584  

 

 

VCA Antech, Inc.

Tomas Fuller, Chief Financial Officer

 

310-571-6505